RESULTS OF LEAD CLINICAL TRIAL IN INTERMEDIATE AMD

INVESTOR PRESENTATION

TOM SPURLING, CHRIS BAKER
21 SEPTEMBER 2018
DISCLAIMER

This presentation has been prepared by Ellex Medical (Ellex, ELX: ASX). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statement. These forward-looking statement have been made based upon Ellex’s expectations and beliefs concerning future developments and their potential effect on Ellex (and it’s controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Ellex’s control. No assurance is given that future developments will be in accordance with Ellex’s expectations. Actual results could differ materially from those expected by Ellex. This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.
Contents

- Overview of LEAD Clinical Trial
- Overview of Intermediate Age-related Macular Degeneration (iAMD)
- Overview of Ellex 2RT® Therapy
- Key Results from LEAD contained in *Ophthalmology* Scientific Publication
- Trial Conclusions
- Market Dynamics and Commercial Opportunity
- Q&A
Overview of LEAD Clinical Trial

The LEAD trial has validated the safety and efficacy of Ellex 2RT® as an intervention for many people with intermediate AMD.

- Double-masked, randomised, sham-controlled trial over 36 months in 292 patients with iAMD across six sites with 1:1 randomisation to Ellex 2RT® or sham treatment received at six monthly intervals
- Primary endpoint – progression to advanced AMD in treated eye of Ellex 2RT® pts versus sham patients
- Secondary endpoints – safety, change in drusen volume and visual function, progression to advanced AMD in non-study eye
- Sub Group – post hoc analysis on patients without coexistent reticular pseudodrusen (RPD) deposits representing 76% of enrolled patients versus 24% with RPD at baseline

- Largest ever randomised study conducted in iAMD patients with a non-thermal, non-invasive pulse laser intervention
- First randomised study in iAMD to utilise modern multi-modal imaging (MMI) techniques to detect and define AMD and greater power to detect treatment effects (e.g. OCT, NIR, FAF and CFP)
- Rationally designed following successful pilot study in 50 patients published in 2013

---

1 Guymer RH, et al. Sub-Threshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmol 2018; In press
2 OCT – optical coherence tomography; NIR- near infrared imaging; FAF – fundus autofluorescence; CFP - colour fundus photography
Overview of iAMD

AMD ("Age-Related Macular Degeneration"):  
• leading cause of blindness in the developed world  
• affects one in seven Australians over the age of 50¹

Unmet need: late stage AMD is treated with 6 weekly injections of drugs directly into a patient’s eye. This can help to preserves vision, but long-term people lose vision due to scarring. Further:  
• onerous on patients and caregivers, and;  
• burden for government health schemes to purchase the drugs

¹. Macular Disease Foundation, Access Economics

iAMD AND THE LEAD TRIAL

• One of the goals of the LEAD trial was to examine whether Ellex 2RT® could delay iAMD to more advanced forms of the disease, where retinal function declines markedly and vision becomes impaired.

• Treatments for late AMD are limited to regular injections of anti-VEGF drugs to the back of the eye.
Indication of retinal health failing, as shown in retinal imaging

Disease progression without Ellex 2RT®

Injection in eye

75 years of age

Detection

Ellex 2RT® to slow disease progression

Apply Ellex 2RT® nanopulse laser light therapy

Good/Normal

Defer injection in eye

Requiring anti-VEGF injection into eye to prevent severe vision loss
Overview of Ellex 2RT®

Ellex 2RT® is Ellex’s proprietary, patented laser therapy that stimulates the eye’s natural healing response to treat the early stages of AMD.

- Specially designed rapid nanosecond pulse, non-thermal laser intervention targeting selected retinal pigment epithelium (RPE) cells to promote extracellular repair mechanism and rejuvenation of the retina
- Technology underpinned by a significant patent portfolio until 2035
- CE Mark for Diabetic Macular Edema (DME) in 2012 and early AMD in 2014
- FDA Clearance for Clinically Significant Macular Edema (CSME) in 2013
- Limited installed base to date; clinicians awaiting further clinical evidence from LEAD trial
- First of Ellex’s laser platforms to incorporate per procedure fee software
Consort Diagram

- 79.6% of patients assessed were randomised into trial
- Intent-to-Treat (ITT) analysis on 292 patients
- Protocol deviations/lost to follow up of 14% in sham group versus 19% in 2RT® treatment group
- Per protocol (PP) analysis on 243 patients
Patient Baseline Characteristics

- Patient baseline demographics and baseline ocular characteristics were well balanced between the two ITT arms
- No significant difference in each of the baseline characteristics noted (p>0.05), with exception of Lutein-Vision intake higher in sham treatment arm

1 Lek JJ et al. Subthreshold Nanosecond Laser Intervention in Intermediate Age-Related Macular Degeneration: Study Design and Baseline Characteristics of the Laser in Early Stages of Age-Related Macular Degeneration Study (Report Number 1). Ophthalmology Retina 2017

<table>
<thead>
<tr>
<th>Demographics</th>
<th>SNL treatment (n=147)</th>
<th>Sham treatment (n=145)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>70.3 (7.0)</td>
<td>69.8 (8.1)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>103 (70.1%)</td>
<td>112 (77.2%)</td>
</tr>
<tr>
<td>Ethnicity (Anglo-Saxon)</td>
<td>134 (91.2%)</td>
<td>128 (88.3%)</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>77 (52.4%)</td>
<td>77 (53.1%)</td>
</tr>
<tr>
<td>Past or current</td>
<td>70 (47.6%)</td>
<td>68 (46.9%)</td>
</tr>
<tr>
<td>Macu-Vision® intake (yes)</td>
<td>50 (34.0%)</td>
<td>45 (31.0%)</td>
</tr>
<tr>
<td>Lutein-Vision® intake (yes)</td>
<td>9 (6.1%)</td>
<td>24 (16.6%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study eye ocular characteristics</th>
<th>SNL treatment (n=147)</th>
<th>Sham treatment (n=145)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCVA (number of letters)</td>
<td>83 [80, 87]</td>
<td>84 [79, 88]</td>
</tr>
<tr>
<td>Pigmentary abnormalities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definitely present</td>
<td>46 (31.3%)</td>
<td>51 (35.2%)</td>
</tr>
<tr>
<td>Absent or questionable</td>
<td>101 (68.7%)</td>
<td>94 (64.8%)</td>
</tr>
<tr>
<td>Reticular pseudodrusen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definitely present</td>
<td>35 (23.8%)</td>
<td>35 (24.1%)</td>
</tr>
<tr>
<td>Absent or questionable</td>
<td>112 (76.2%)</td>
<td>110 (75.9%)</td>
</tr>
</tbody>
</table>

Data are frequency (%), mean (standard deviation) or median [25th to 75th percentile]. SNL = sub-threshold nanosecond laser. BCVA = best-corrected visual acuity. * = active ingredients of Macu-Vision® include Vitamin C, Vitamin E, zinc oxide, cupric oxide. # = active ingredients of Lutein-Vision® include Lutein, Selenomethionine, Zeaxanthin, omega-3 triglycerides-fish oil.
Safety

- Ellex 2RT® was well tolerated with no statistically significant difference in Serious Adverse Events (SAEs) reported.
- Ocular Adverse Events (AEs) with Ellex 2RT® were retinal haemorrhages that resolved in all cases without any untoward sequelae.
- All other adverse events recorded were statistically no different between the Ellex 2RT® treatment group and sham group.
- 3.4% of patients reported after-images >1 day after treatment.
- No difference between the groups in events unrelated to the progression to late AMD.

Table 2: Number and proportion of patients with adverse events

<table>
<thead>
<tr>
<th>Event Category</th>
<th>SNL treatment (n=147)</th>
<th>Sham treatment (n=145)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definitely related ocular adverse events</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants reporting one or more adverse events</td>
<td>15 (10-2%)</td>
<td>1 (0-7%)</td>
</tr>
<tr>
<td>After-images*</td>
<td>5 (3-4%)</td>
<td>1 (0-7%)</td>
</tr>
<tr>
<td>Retinal haemorrhage</td>
<td>10 (6-8%)</td>
<td>0 (0-0%)</td>
</tr>
<tr>
<td><strong>Possibly related ocular adverse events</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants reporting one or more adverse events</td>
<td>25 (17-0%)</td>
<td>24 (16-6%)</td>
</tr>
<tr>
<td>Epiretinal membrane</td>
<td>1 (0-7%)</td>
<td>4 (2-8%)</td>
</tr>
<tr>
<td>Symptomatic PVD or floaters</td>
<td>8 (5-4%)</td>
<td>5 (3-4%)</td>
</tr>
<tr>
<td>Ocular discomfort following treatment</td>
<td>7 (4-8%)</td>
<td>11 (7-6%)</td>
</tr>
<tr>
<td>Cataract requiring surgery</td>
<td>3 (2-0%)</td>
<td>2 (1-4%)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (2-0%)</td>
<td>5 (3-4%)</td>
</tr>
<tr>
<td><strong>Other adverse events</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrelated ocular adverse events</td>
<td>81 (55-1%)</td>
<td>70 (48-3%)</td>
</tr>
<tr>
<td>Non-ocular adverse events</td>
<td>103 (70-1%)</td>
<td>109 (75-2%)</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants reporting one or more serious adverse events</td>
<td>56 (38-1%)</td>
<td>50 (34-5%)</td>
</tr>
<tr>
<td>Cardiovascular or cerebrovascular disorders</td>
<td>14 (9-5%)</td>
<td>13 (9-0%)</td>
</tr>
<tr>
<td>Death (unknown cause)</td>
<td>0 (0-0%)</td>
<td>1 (0-7%)</td>
</tr>
<tr>
<td>Infections</td>
<td>8 (5-4%)</td>
<td>2 (1-4%)</td>
</tr>
<tr>
<td>Injury and procedural complications</td>
<td>10 (6-8%)</td>
<td>9 (6-2%)</td>
</tr>
<tr>
<td>Neoplasms (benign and malignant)</td>
<td>7 (4-8%)</td>
<td>8 (5-5%)</td>
</tr>
<tr>
<td>Nervous system disorder</td>
<td>3 (2-0%)</td>
<td>3 (2-1%)</td>
</tr>
<tr>
<td>Respiratory disorder</td>
<td>5 (3-4%)</td>
<td>3 (2-1%)</td>
</tr>
<tr>
<td>Surgery and medical procedures</td>
<td>7 (4-8%)</td>
<td>5 (3-4%)</td>
</tr>
<tr>
<td>Other (medical)</td>
<td>23 (15-6%)</td>
<td>22 (15-2%)</td>
</tr>
</tbody>
</table>

Data are number of participants (%).  *PVD = posterior vitreous detachment.  * = visible for more than one day, as reported at the one-week phone call after the initial treatment.

Table 2: Number and proportion of patients with adverse events.
Primary Endpoint Results

- No significant difference in progression to late AMD under ITT analysis (p=0.122) or the PP analysis (p=0.092)
- At 36 months, 13.6% progressed to late AMD in the 2RT® treatment group versus 17.2% in the sham eye (ITT)
- At 36 months, 15.1% progressed to late AMD in the 2RT® treatment group versus 20.2% in sham eye (PP)
- Non-significant trend in favour of the 2RT® treatment group

* Adjusted Hazard Ratio (HR) - The potential confounders of baseline age (as a continuous measure), sex, intake of Lutein-Vision® or Macu-Vision® at baseline (yes vs. no for each), presence of RPD and pigmentary abnormalities (definitely present vs. absent/questionable) were additionally included as covariates in a fully adjusted model as specified a priori
Treatment Effect on Late AMD

- Estimated effect on Forest plot of 2RT® examining the two phenotypes of late AMD (neovascular AMD and drusen-associated atrophy)
- Pronounced treatment effect on drusen-associated atrophy favouring 2RT® (HR=0.53)
A clinically meaningful 77% reduction in the risk of progression (HR=0.23) in patients who received 2RT® versus sham.

2RT® showed a significant treatment effect in this patient population (p=0.002).

RPD is a key biomarker of retinal pigment epithelium (RPE) dysfunction and has a high association with progression to late-stage AMD.

The 76% of patients without baseline RPD enrolled in LEAD approximates incidence rates in prospective studies, thereby representing a large, clinically important group with no treatments currently approved.
Patients with RPD at Baseline - Analysis

- Increased rate of progression to late-stage AMD in the 2RT® treatment group compared to the sham treatment group, although the treatment effect was not significant (p=0.112 for ITT and p=0.258 for PP analysis)

- Ellex 2RT’s mechanism of action requires the selective loss and subsequent healing of the RPE, there may be a stage of AMD disease whereby RPE integrity is so greatly compromised as to render treatment with Ellex 2RT® is unsuitable

- Such data is clinically valuable in selecting patients who are likely to respond to Ellex 2RT®
LEAD Trial Conclusions

- Though the primary endpoint across the entire study cohort was not met, Ellex 2RT® displayed an exceptional safety profile.
- Patients with no reticular pseudodrusen (RPD) deposits at baseline had a 77% reduction in the risk of progression to late stage AMD at any stage during the trial, which was conducted over three years.
- This result is highly clinically meaningful and showed a remarkable treatment effect.
- RPD negative sub group represents approximately 75% of all iAMD patients with bilateral large drusen and no geographic atrophy.
- LEAD was the first ever trial to show significant efficacy in an iAMD population.
- Important new clinical information to guide retinal specialists in patient selection towards those without evidence of RPD.
- Results are applicable only to Ellex 2RT® – authors discourage extrapolation of results to other thermal or non-thermal lasers.
Market Dynamics and Commercial Opportunity

- Publication in *Ophthalmology*, the most important peer-reviewed ophthalmology journal globally, underscores the significance of the clinical results.\(^1\)

- Where Ellex 2RT® is approved for AMD, these markets represent an addressable market of 15 million patients per annum for screening and then treating those early stage patients without detectable RPD.\(^2\)

- Addressable market similar in size (patients) to late stage ‘wet’ AMD

- Ellex’s commercialisation plan will be developed based on physician feedback, peer-to-peer educational programs focused on disease diagnosis, patient selection and treatment protocols

- Future regulatory clearances in the US, Japan and China will increase the pool of treatable patients to 25 million per annum.\(^3\)

- No currently approved treatments for iAMD – only dietary and lifestyle modifications (a standard that resulted from analysis of the AREDS1 and AREDS2 studies).\(^4,5\)

- Therapeutic approvals have been limited to late stage ‘wet’ AMD, which represents the minority of AMD patients

- Ellex intends to explore regulatory requirements for the US market

---

2. Marketscope Report August 2017 Ophthalmic Laser Report Table 2 “Global Forecast for AMD in all its Forms”, adjusted for Ellex estimates on RPD patients
3. Up in the USA, China and Japan
THANK YOU
Q/A SESSION